Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zhang X, Sountis MM, Santoprete A, Capito' E, Chicchi GG, Thornberry N, Bianchi E, Pessi A, Marsh DJ, SinhaRoy R. Pocai A, et al. Diabetes. 2009 Oct;58(10):2258-66. doi: 10.2337/db09-0278. Epub 2009 Jul 14. Diabetes. 2009. PMID: 19602537 Free PMC article.
DPP-IV-resistant, long-acting oxyntomodulin derivatives.
Santoprete A, Capitò E, Carrington PE, Pocai A, Finotto M, Langella A, Ingallinella P, Zytko K, Bufali S, Cianetti S, Veneziano M, Bonelli F, Zhu L, Monteagudo E, Marsh DJ, Sinharoy R, Bianchi E, Pessi A. Santoprete A, et al. Among authors: pocai a. J Pept Sci. 2011 Apr;17(4):270-80. doi: 10.1002/psc.1328. Epub 2011 Feb 3. J Pept Sci. 2011. PMID: 21294225
Moreover, we identified a single substitution which can change the OXM pharmacological profile from a dual GLP1R/GCGR agonist to a selective GLP1R agonist. The latter finding enabled studies, described in detail in a separate study (Pocai A …
Moreover, we identified a single substitution which can change the OXM pharmacological profile from a dual GLP1R/GCGR agonist …
Differential effects of oxyntomodulin and GLP-1 on glucose metabolism.
Du X, Kosinski JR, Lao J, Shen X, Petrov A, Chicchi GG, Eiermann GJ, Pocai A. Du X, et al. Among authors: pocai a. Am J Physiol Endocrinol Metab. 2012 Jul 15;303(2):E265-71. doi: 10.1152/ajpendo.00142.2012. Epub 2012 May 22. Am J Physiol Endocrinol Metab. 2012. PMID: 22621866 Free article.
Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide.
Neuner P, Peier AM, Talamo F, Ingallinella P, Lahm A, Barbato G, Di Marco A, Desai K, Zytko K, Qian Y, Du X, Ricci D, Monteagudo E, Laufer R, Pocai A, Bianchi E, Marsh DJ, Pessi A. Neuner P, et al. Among authors: pocai a. J Pept Sci. 2014 Jan;20(1):7-19. doi: 10.1002/psc.2582. Epub 2013 Nov 13. J Pept Sci. 2014. PMID: 24222478
Glucagon like receptor 1/ glucagon dual agonist acutely enhanced hepatic lipid clearance and suppressed de novo lipogenesis in mice.
More VR, Lao J, McLaren DG, Cumiskey AM, Murphy BA, Chen Y, Previs S, Stout S, Patel R, Satapati S, Li W, Kowalik E, Szeto D, Nawrocki A, Pocai A, Wang L, Carrington P. More VR, et al. Among authors: pocai a. PLoS One. 2017 Oct 24;12(10):e0186586. doi: 10.1371/journal.pone.0186586. eCollection 2017. PLoS One. 2017. PMID: 29065174 Free PMC article.
A comparative study of the binding properties, dipeptidyl peptidase-4 (DPP-4) inhibitory activity and glucose-lowering efficacy of the DPP-4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice.
Berger JP, SinhaRoy R, Pocai A, Kelly TM, Scapin G, Gao YD, Pryor KAD, Wu JK, Eiermann GJ, Xu SS, Zhang X, Tatosian DA, Weber AE, Thornberry NA, Carr RD. Berger JP, et al. Among authors: pocai a. Endocrinol Diabetes Metab. 2017 Nov 24;1(1):e00002. doi: 10.1002/edm2.2. eCollection 2018 Jan. Endocrinol Diabetes Metab. 2017. PMID: 30815539 Free PMC article.
59 results